A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

Clinical trial NCT04489771 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04489771
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Renal Cell

Start date: 2020-09-13
Primary completion: 2023-02-10
Enrollment: 154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.